Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 641 - 660 results of 104,229 for search '(( 2 w decrease ) OR ( 5 ((((wt decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.35s Refine Results
  1. 641
    Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study

    Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

    Published 2017
    Save to List
    Saved in:
  2. 642
    Decreased CCL2 levels protect A20<sup>AEC-KO</sup> mice against influenza A infection

    Decreased CCL2 levels protect A20<sup>AEC-KO</sup> mice against influenza A infection by Jonathan Maelfait (181048)

    Published 2016
    Save to List
    Saved in:
  3. 643
    PM exposure affects small airways to a greater degree in WT compared to Ager<sup>-/-</sup> mice.

    PM exposure affects small airways to a greater degree in WT compared to Ager<sup>-/-</sup> mice. by Erin J. Caraher (4445902)

    Published 2017
    “…<p>(A) WT-PM mice had significantly elevated tissue resistance at 1Hz p<0.001 (*). …”
    Save to List
    Saved in:
  4. 644
    Data_Sheet_2_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.CSV

    Data_Sheet_2_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.CSV by Brian E. Sedio (10875330)

    Published 2021
    “…In contrast, chemical similarity of co-occurring species decreased with both MAT and MAP, and metabolite richness increased with MAT. …”
    Save to List
    Saved in:
  5. 645
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 646
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 647
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 648
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 649
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 650
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 651
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 652
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 653
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 654
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 655
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 656
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 657
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 658
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 659
    MDSCs decrease the frequency of Th17 cells in mice with DSS-induced colitis.

    MDSCs decrease the frequency of Th17 cells in mice with DSS-induced colitis. by Jing Zhang (23775)

    Published 2013
    “…A) Adoptive transfer of MDSCs decreased serum IL-17 level in DSS-treated WT mice. …”
    Save to List
    Saved in:
  20. 660
    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins.

    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins. by Jin Ou (16914305)

    Published 2023
    Save to List
    Saved in:

Search Tools: